scispace - formally typeset
L

Laufey Tryggvadottir

Researcher at University of Iceland

Publications -  276
Citations -  21735

Laufey Tryggvadottir is an academic researcher from University of Iceland. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 63, co-authored 270 publications receiving 18070 citations. Previous affiliations of Laufey Tryggvadottir include Lund University & Carlos III Health Institute.

Papers
More filters
Journal ArticleDOI

Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Claudia Allemani, +594 more
- 17 Mar 2018 - 
TL;DR: For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden, while for many cancers, Denmark is closing the survival gap with the other Nordic countries.
Journal ArticleDOI

Alcohol, tobacco and breast cancer - Collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease

Nobuyuki Hamajima, +219 more
TL;DR: In conclusion, smoking has little or no independent effect on the risk of developing breast cancer; the effect of alcohol on breast cancer needs to be interpreted in the context of its beneficial effects, in moderation, on cardiovascular disease and its harmful effects on cirrhosis.
Journal ArticleDOI

Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies

Nobuyuki Hamajima, +292 more
- 01 Nov 2012 - 
TL;DR: The effects of menarche and menopause on breast cancer risk might not be acting merely by lengthening women's total number of reproductive years, and endogenous ovarian hormones are more relevant for oestrogen receptor-positive disease than for ostrogens receptor-negative disease and for lobular than for ductal tumours.